Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases
- 27 November 2000
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 12 (6) , 712-718
- https://doi.org/10.1016/s0952-7915(00)00167-9
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot studyAnnals of the Rheumatic Diseases, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgarisJournal of Clinical Investigation, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisPublished by Elsevier ,1999
- Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease (STAMM-CD)Gastroenterology, 1998
- Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study GroupGastroenterology, 1997
- Dose‐range and dose‐frequency study of recombinant human interleukin‐1 receptor antagonist in patients with rheumatoid arthritisArthritis & Rheumatism, 1996
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994